Compare Amylx Pharmaceuticals Inc (AMLX) vs Canadian National Railway Co. (CNI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Canadian National Railway Co. — how do they compare? Amylx Pharmaceuticals Inc trades at $23.66 (market cap $2.64B), while Canadian National Railway Co. trades at $126.42 (market cap $76.28B). The key difference: Canadian National Railway Co. is far larger — about 28.9× Amylx Pharmaceuticals Inc's market cap, and Canadian National Railway Co. pays a 2.06% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | CNI | |
|---|---|---|
Market Cap | $2.64B | $76.28B |
Sector | Health | Industrials |
52-Week High | $24.19 | $130.58 |
52-Week Low | $7.82 | $90.91 |
Enterprise Value | $2.39B | $92.31B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Canadian National Railway (CNI) trades at $125.14, down 1.15% with a bearish technical signal. The company reported strong Q2 2026 results with EPS of $1.50 beating estimates by 7.9% and raised full-year guidance, driven by record grain volumes and improved operational efficiency. Fundamentals show solid profitability with 26.92% net margin and 22.02% ROE, though valuation multiples appear elevated with P/E of 22.62. Recent news highlights continued infrastructure investment and customer growth projects exceeding $2 billion in 2025.
CNI presents a mixed outlook with strong operational execution offset by valuation concerns. The 21.8% upside to consensus price target of $152.38 offers potential, but rising debt levels and competitive pressures pose risks. Analyst sentiment is cautious with 60.79% hold ratings, suggesting waiting for clearer evidence of sustained earnings growth before committing new capital.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Canadian National Railway Co.
Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2019, CN delivered almost 6 million carloads over its 19,600 miles of track. CN generated roughly CAD 14 billion in total revenue by hauling intermodal containers (25% of consolidated revenue), petroleum and chemicals (21%), grain and fertilizers (16%), forest products (12%), metals and mining (11%), automotive shipments (6%), and coal (4%). Other items constitute the remaining revenue.
Read more on CNI →
